alexa
Reach Us +44-1904-929220
Copro-antiapoptotic Protein Survivin And Lactoferrin Biomarkers For Improved Detection And Nanodelivery To Colon Cancer | 3654
ISSN-2155-9929

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Copro-antiapoptotic protein survivin and lactoferrin biomarkers for improved detection and nanodelivery to colon cancer

2nd World Congress on Biomarkers & Clinical Research

Jagat R Kanwar, Ganesh Mahidhara, Rupinder K Kanwar and Chun Hei Antonio Cheung

ScientificTracks Abstracts: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.2

Abstract
We and others have found that survivin, a member of the family of inhibitor of apoptosis proteins that is overexpressed in several human tumours. Lactoferrin is also known to express in infl ammatory diseases such as infl ammatory bowel disease and Crohn?s disease. We assessed the diff erential expression of survivin, other apoptotic biomarkers and lactoferrin in stool and serum samples of colorectal cancer (CRC) patients. We compared serum and stool samples from CRC patients and samples from healthy volunteers using an in vitro enzyme- linked immunosorbent assay to evaluate the survivin and lactoferrin response in patients. Th e sensitivity of the anti-survivin and lactoferrin response from patients with CRC was 65% and 70%, the specifi city was 62% and 75% respectively with good predictive positivity and predictive negativity. Combined detection using survivin and lactoferrin produced better sensitivity (65%) and specifi city (90%), respectively). In conclusion a positive association between survivin and lactoferrin concentrations in sera and stool samples of patients with CRCs was established. Our results suggest that analysis of both parameters would assist in screening patients with CRC. Our fi ndings also suggest that the reduction in the serum survivin and copro-lactoferrin levels of advanced CRC patients aft er chemotherapy can be used as a predictor of response to the chemotherapy but not that of survival. In addition, we developed dominant negative mutant of survivin (SurR9-C84A) and loaded into Alginate enclosed chitosan- calcium phosphate nano carriers (ACSC-NCs), in order to improve the oral bioavailability and to protect the peptide from the locale of gastro intestinal tract. Th ese CSC-NCs loaded with SurR9-C84A were tested in a xenograft mice model of colon cancer. We found all tumor bearing mice regressed tumors signifi cantly. Anti-tumor activity was mediated by inducing apoptosis and necrosis in tumours. Th ere was signifi cant decrease in angiogenesis and vasculature in the CSC NCs-SurR9-C84A as compared to empty CSC-NCs ingested control tumor mice. In the present study we developed a safe, nontoxic, mucoadhesive, completely biodeg radable, compatible and sustain released CSC- NCs as a proof of concept in colon cancer which can be used for other cancer types. Th us these CSC-NCs can be exploited for oral administration to protect from variable pH in intestinal track and resistance to gastric enzymes which othe rwise digest proteins in gastrointestinal tract
Biography
We and others have found that survivin, a member of the family of inhibitor of apoptosis proteins that is overexpressed in several human tumours. Lactoferrin is also known to express in infl ammatory diseases such as infl ammatory bowel disease and Crohn?s disease. We assessed the diff erential expression of survivin, other apoptotic biomarkers and lactoferrin in stool and serum samples of colorectal cancer (CRC) patients. We compared serum and stool samples from CRC patients and samples from healthy volunteers using an in vitro enzyme- linked immunosorbent assay to evaluate the survivin and lactoferrin response in patients. Th e sensitivity of the anti-survivin and lactoferrin response from patients with CRC was 65% and 70%, the specifi city was 62% and 75% respectively with good predictive positivity and predictive negativity. Combined detection using survivin and lactoferrin produced better sensitivity (65%) and specifi city (90%), respectively). In conclusion a positive association between survivin and lactoferrin concentrations in sera and stool samples of patients with CRCs was established. Our results suggest that analysis of both parameters would assist in screening patients with CRC. Our fi ndings also suggest that the reduction in the serum survivin and copro-lactoferrin levels of advanced CRC patients aft er chemotherapy can be used as a predictor of response to the chemotherapy but not that of survival. In addition, we developed dominant negative mutant of survivin (SurR9-C84A) and loaded into Alginate enclosed chitosan- calcium phosphate nano carriers (ACSC-NCs), in order to improve the oral bioavailability and to protect the peptide from the locale of gastro intestinal tract. Th ese CSC-NCs loaded with SurR9-C84A were tested in a xenograft mice model of colon cancer. We found all tumor bearing mice regressed tumors signifi cantly. Anti-tumor activity was mediated by inducing apoptosis and necrosis in tumours. Th ere was signifi cant decrease in angiogenesis and vasculature in the CSC NCs-SurR9-C84A as compared to empty CSC-NCs ingested control tumor mice. In the present study we developed a safe, nontoxic, mucoadhesive, completely biodeg radable, compatible and sustain released CSC- NCs as a proof of concept in colon cancer which can be used for other cancer types. Th us these CSC-NCs can be exploited for oral administration to protect from variable pH in intestinal track and resistance to gastric enzymes which othe rwise digest proteins in gastrointestinal tract
Relevant Topics
Top